Journal of Endocrine Surgery

Korean Association of Thyroid and Endocrine Surgeons (대한갑상선내분비외과학회)
권호 표지
DOI QR코드

DOI QR Code

EGFR and HER2 Expression in Papillary Thyroid Carcinoma

  • Kim, Yong-Seon (Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jeong-Soo (Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Yong-Seok (Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2018.11.11
  • Accepted : 2018.12.13
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: The epidermal growth factor receptor (EGFR) family plays a crucial role in the growth of malignant tumors. EGFR and human EGFR 2 (HER2) protein overexpression are associated with an unfavorable prognosis and are important therapeutic targets in breast cancer. The aim of this study was to evaluate the relationship between EGFR and HER2 expression and clinicopathological factors in papillary thyroid carcinoma (PTC) at a single institution. Methods: A total of 129 consecutive patients with PTC were enrolled in this study and underwent thyroid surgery between October 2013 and February 2015. EGFR and HER2 protein expression was evaluated in the 129 primary tumors by immunohistochemistry, and the results were compared with the clinicopathological features. Results: Of the 129 PTC tumors, 20 (15.5%) were HER2 positive, and 109 (84.5%) were HER2 negative. Moreover, EGFR positivity were observed in 111 (86%) tumors. The mean age of the patients was $46.3{\pm}11.9years$ (range, 20-74 years), and the mean tumor size was $1.08{\pm}0.75cm$ (range, 0.2-3.5 cm). Tumor size, extrathyroidal extension, histological subtype, and TNM stage were not significantly associated with EGFR or HER2 expression. Meanwhile, high Ki-67 labeling index was significantly associated with EGFR expression (P=0.002), HER2 expression was significantly associated with younger age (${\leq}45years$) and cervical lymph node metastasis. Conclusion: Based on our data, it is not clear whether EGFR and HER2 expression is associated with tumor aggressiveness in PTC.

Keywords

References

  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7. https://doi.org/10.1001/jama.295.18.2164
  2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.
  3. Kim YS, Park WC. Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma. World J Surg Oncol 2012;10:164. https://doi.org/10.1186/1477-7819-10-164
  4. Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-28. https://doi.org/10.1016/S1726-4901(10)70025-3
  5. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22:395-404. https://doi.org/10.1016/j.clon.2010.05.004
  6. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-21. https://doi.org/10.3349/ymj.2004.45.5.818
  7. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70. https://doi.org/10.1097/SLA.0b013e318148563d
  8. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid 2013;23:1277-83. https://doi.org/10.1089/thy.2013.0057
  9. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
  10. Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res 2013;185:217-24. https://doi.org/10.1016/j.jss.2013.05.003
  11. Ensinger C, Prommegger R, Kendler D, Gabriel M, Spizzo G, Mikuz G, et al. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Res 2003;23:2349-53.
  12. Sugishita Y, Kammori M, Yamada O, Poon SS, Kobayashi M, Onoda N, et al. Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening. Int J Oncol 2013;42:1589-96. https://doi.org/10.3892/ijo.2013.1848
  13. Rebai M, Kallel I, Hamza F, Charfeddine S, Kaffel R, Guermazi F, et al. Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer. Genet Test Mol Biomarkers 2009;13:779-84. https://doi.org/10.1089/gtmb.2009.0068
  14. Freudenberg LS, Sheu S, Gorges R, Mann K, Bokler S, Frilling A, et al. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin 2005;44:179-82, 184. https://doi.org/10.1055/s-0038-1625202
  15. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-7.
  16. Verkooijen HM, Fioretta G, Pache JC, Franceschi S, Raymond L, Schubert H, et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control 2003;14:13-7. https://doi.org/10.1023/A:1022593923603
  17. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009;20:648-54. https://doi.org/10.1093/annonc/mdn681
  18. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
  19. Mitrasinovic PM. Epidermal growth factor receptors: a functional perspective. Curr Radiopharm 2012;5:29-33. https://doi.org/10.2174/1874471011205010029
  20. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 Suppl 4:31-9. https://doi.org/10.1634/theoncologist.7-suppl_4-31
  21. Tang C, Yang L, Wang N, Li L, Xu M, Chen GG, et al. High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol 2014;7:3213-23.
  22. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012;132:895-915. https://doi.org/10.1007/s10549-011-1837-z
  23. Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, et al. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha}$ expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev 2015;16:823-9. https://doi.org/10.7314/APJCP.2015.16.2.823
  24. Saha R, Chatterjee U, Mandal S, Saha K, Chatterjee S, Ghosh SN. Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: a prospective study in a tertiary care hospital. Indian J Med Paediatr Oncol 2014;35:149-55. https://doi.org/10.4103/0971-5851.138983
  25. Tang W, Nakamura Y, Zuo H, Yasuoka H, Yang Q, Wang X, et al. Differentiation, proliferation and retinoid receptor status of papillary carcinoma of the thyroid. Pathol Int 2003;53:204-13. https://doi.org/10.1046/j.1320-5463.2003.01456.x
  26. Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A. Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma. World J Surg 2010;34:3015-21. https://doi.org/10.1007/s00268-010-0746-3
  27. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 2003;13:371-80. https://doi.org/10.1089/105072503321669866
  28. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-52.
  29. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-8. https://doi.org/10.1007/s00268-009-0142-z